Previous 10 | Next 10 |
Cathie Wood unloaded just over 100K shares of Exact Sciences ( NASDAQ: EXAS ) on Tuesday a few weeks after her team predicted that the stock could nearly triple in value by the year 2027. Since that call, EXAS has climbed more than 35%. In total, Wood sold 100,326 shares of EXAS throu...
Veracyte (NASDAQ: VCYT) and Exact Sciences (NASDAQ: EXAS) focus on genomic tests to diagnose various cancers. It's an area that is expanding wildly. A report by BIS Research puts the molecular cancer diagnostics market at $4.1 billion in 2022 but with a compound annual growth rate (...
Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...
Early cancer detection is a lot more common these days than it was a decade ago. Exact Sciences (NASDAQ: EXAS) can't claim all the credit, but the non-invasive cancer tests that it markets play an important role. The company's cancer tests screened around 4 million people in 2021. Des...
Summary NVTA Q4 cash balance remained flat year-over-year at $555M, with 2022 revenue declining by $4M to $122M. Shares appreciated 25% after last week's Q4 purview on optimism over management's ability to trim operating costs, which would provide NVTA with sufficient runway to execute ...
This year, Exact Sciences (NASDAQ: EXAS) expects its revenue will total just under $2.1 billion. That means that in just five years, its top line will have grown by an incredible 683%. The company has achieved significant growth over the years as its cancer screening tests have gaine...
Summary Despite its price surge, EXAS's valuation remains aligned with industry averages. EXAS has one of the clearest profitability paths in a market characterized by heavy losses stemming from aggressive growth initiatives. We might see some profit-taking in the coming weeks, but ...
Summary ARK Invest's Cathie Wood believes Exact Sciences (EXAS) can hit $140 per share by 2027. Unlike some other calls, I believe Cathie and ARK are spot-on with EXAS. EXAS is a major holding in both Cathie's ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG). Together, it...
Molecular diagnostics company Exact Sciences ( NASDAQ: EXAS ) expects total fourth quarter revenue growth (excluding COVID-19 testing) of 28% Y/Y, with screening revenue of $401.8M-$402.8M (+45%) and precision oncology revenue of $142.9M-$143.9M (-4%). Q4 revenue is estimated betw...
Exact Sciences Announces Preliminary Fourth Quarter 2022 Results PR Newswire Preliminary fourth quarter highlights: Expected total fourth quarter revenue, excluding COVID - 19 testing, increased 28% compared to the fourth quarter 2021, with Screening revenue of $...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...